Source:http://linkedlifedata.com/resource/pubmed/id/10901708
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
8
|
pubmed:dateCreated |
2000-9-8
|
pubmed:abstractText |
This study demonstrates the stereoselective metabolism of the optical isomers of omeprazole in human liver microsomes. The intrinsic clearance (CL(int)) of the formation of the hydroxy metabolite from S-omeprazole was 10-fold lower than that from R-omeprazole. However, the CL(int) value for the sulfone and 5-O-desmethyl metabolites from S-omeprazole was higher than that from R-omeprazole. The sum of the CL(int) of the formation of all three metabolites was 14.6 and 42.5 microl/min/mg protein for S- and R-omeprazole, respectively. This indicates that S-omeprazole is cleared more slowly than R-omeprazole in vivo. The stereoselective metabolism of the optical isomers is mediated primarily by cytochrome P450 (CYP) 2C19, as indicated by studies using cDNA-expressed enzymes. This is the result of a considerably higher CL(int) of the 5-hydroxy metabolite formation for R- than for S-omeprazole. For S-omeprazole, CYP2C19 is more important for 5-O-desmethyl formation than for 5-hydroxylation. Predictions of the CL(int) using data from cDNA-expressed enzymes suggest that CYP2C19 is responsible for 40 and 87% of the total CL(int) of S- and R-omeprazole, respectively, in human liver microsomes. According to experiments using cDNA-expressed enzymes, the sulfoxidation of both optical isomers is metabolized by a single isoform, CYP3A4. The CL(int) of the sulfone formation by CYP3A4 is 10-fold higher for S-omeprazole than for R-omeprazole, which may contribute to their stereoselective disposition. The results of this study show that both CYP2C19 and CYP3A4 exhibit a stereoselective metabolism of omeprazole. CYP2C19 favors 5-hydroxylation of the pyridine group of R-omeprazole, whereas the same enzyme mainly 5-O-demethylates S-omeprazole in the benzimidazole group. Sulfoxidation mediated by CYP3A4 highly favors the S-form.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/2-Pyridinylmethylsulfinylbenzimidazo...,
http://linkedlifedata.com/resource/pubmed/chemical/5-hydroxymethylomeprazole,
http://linkedlifedata.com/resource/pubmed/chemical/Anti-Ulcer Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Aryl Hydrocarbon Hydroxylases,
http://linkedlifedata.com/resource/pubmed/chemical/CYP2C19 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Cytochrome P-450 Enzyme System,
http://linkedlifedata.com/resource/pubmed/chemical/Isoenzymes,
http://linkedlifedata.com/resource/pubmed/chemical/Mixed Function Oxygenases,
http://linkedlifedata.com/resource/pubmed/chemical/Omeprazole,
http://linkedlifedata.com/resource/pubmed/chemical/omeprazole sulfone
|
pubmed:status |
MEDLINE
|
pubmed:month |
Aug
|
pubmed:issn |
0090-9556
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
28
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
966-72
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:10901708-2-Pyridinylmethylsulfinylbenzimidazoles,
pubmed-meshheading:10901708-Anti-Ulcer Agents,
pubmed-meshheading:10901708-Aryl Hydrocarbon Hydroxylases,
pubmed-meshheading:10901708-Cytochrome P-450 Enzyme System,
pubmed-meshheading:10901708-Humans,
pubmed-meshheading:10901708-Isoenzymes,
pubmed-meshheading:10901708-Kinetics,
pubmed-meshheading:10901708-Microsomes, Liver,
pubmed-meshheading:10901708-Mixed Function Oxygenases,
pubmed-meshheading:10901708-Omeprazole,
pubmed-meshheading:10901708-Stereoisomerism
|
pubmed:year |
2000
|
pubmed:articleTitle |
Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes.
|
pubmed:affiliation |
AstraZeneca R&D Mölndal, Mölndal, Sweden. angela.abelo@astrazeneca.com
|
pubmed:publicationType |
Journal Article,
In Vitro
|